Janux Therapeutics JANX Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | -1,143.1%+73.5pp | -1,576.7%-643pp | -1,442.9%-784pp | -33,002.1%-32,566pp | -1,216.6%-217pp | |
| Net margin | -833.6%-0.9pp | -1,136.3%-485pp | -1,019%-555pp | -24,064%-23,773pp | -832.7%-69.8pp | |
| EBITDA margin | -1,128.7%+66.0pp | -1,556.4%-642pp | -1,422.2%-779pp | -32,527.8%-32,106pp | -1,194.7%-223pp | |
| Free cash flow margin | -571.6%-73.1pp | -832.8%-416pp | -714%-424pp | -13,827.8%-13,512pp | -498.4%+232pp | |
| Returns | ||||||
| Return on equity | -11.7%-2.4pp | -11.5%-1.4pp | -12.5%-0.4pp | -12.8%-3.6pp | -9.3%+2.2pp | |
| Return on assets | -11%-2.1pp | -11%-1.4pp | -11.8%-0.7pp | -12.3%-3.7pp | -8.9%+1.7pp | |
| Return on invested capital | -16.8%-0.9pp | -20.5%0.0pp | -18%-1.0pp | -17.8%-4.0pp | -15.9%+2.9pp | |
| Efficiency | ||||||
| Asset turnover | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Liquidity | ||||||
| Current ratio | 17×-41.5× | 39×-20.2× | 35.9×-2.9× | 47×-10.3× | 58.5×-3.6× | |
| Quick ratio | 17×-41.5× | 39×-20.2× | 35.9×-2.9× | 47×-10.3× | 58.5×-3.6× | |
| Cash ratio | 0.9×-3.3× | 2.1×-22.6× | 1.7×+0.2× | 2.5×+1.2× | 4.2×-15.8× | |
| Leverage | ||||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $15.02-8.3% | $15.44-18.9% | $15.74+31.1% | $16.00+32.5% | $16.39+22.6% | |
| Valuation | ||||||
| Market capitalization | $892.81M-36.3% | $830.04M-73.6% | $1.47B-40.6% | $1.38B-32.8% | $1.6B-13.6% | |
| Enterprise value | $862.55M-36.2% | $799.84M-70.7% | $1.44B-41.6% | $1.35B-34.5% | $1.54B-6.8% | |
| Price / sales | 65×-85.2× | 83×-213× | 146.9×-42.7× | 3,147.5×+3,012× | 170.9×-82.5× | |
| Price / book | 0.9×-0.4× | 0.9×-2.2× | 1.5×-2.3× | 1.4×-1.7× | 1.6×-1.2× | |
| EV / sales | 62.5×-81.6× | 80×-178× | 144.3×-45.0× | 3,078.6×+2,942× | 165.5×-62.1× | |
| Free cash flow yield | -8.8%-5.5pp | -10%-8.6pp | -4.9%-3.3pp | -4.4%-2.1pp | -2.9%0.0pp | |
| Earnings yield | -12.9%-7.3pp | -13.7%-11.5pp | -6.9%-4.5pp | -7.6%-5.5pp | -4.9%-1.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Janux Therapeutics's ratios come from?
- Every ratio is computed from Janux Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
